metformin vs Retagliptin/metformin (Ruilintang)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: AMPK · full Type 2 Diabetes pipeline

metformin · Glucophage

Rights held by National Institute of Allergy and Infectious Diseases (NIAID) and partners; US product discontinued

Approved in Type 2 Diabetessmall molecule
Reliable signal

NCT00004992 · Phase 3 · completed

This was a large, randomized, blinded, placebo-controlled trial with a hard clinical endpoint (new diabetes diagnosis), and metformin significantly reduced diabetes incidence versus placebo by 31% (95% CI 17-43%).

Next expected readout: December 2026 · NCT02087826 (registry estimate)

Reported efficacy

Development of diabetes (Up to 5 years): Diabetes incidence: 11.0 (placebo) vs 7.8 (metformin) vs 4.8 (lifestyle) cases per 100 person-years; metformin reduced incidence by 31% vs placebo (95% CI 17-43%) (met)

Result source: NCT00004992

Retagliptin/metformin (Ruilintang)

Marketed by Jiangsu Hengrui Pharmaceuticals

Phase 1 in Type 2 Diabetessmall molecule combination
Partial signal

NCT05415644 · Phase 1 · completed

This is a randomized, blinded, crossover comparison against the reference formulation, which is a sound design for its purpose, but it measures only drug levels in the blood rather than a diabetes outcome, and no results have been posted yet.

No aligned efficacy figure on record for this race.

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointmetforminRetagliptin/​metformin (Ruilintang)
HbA1c, change0.2% vs 0.1%+0.1 vs placebowk 12 · n 46NCT02099838
14 other results
  • -1.0% vs -1.0% 5 mg once daily + metformin once daily · wk 14 · n 298 · Phase 4 · primary NCT01438814
  • -0.7% vs -0.9% 0.2 mg · wk 12 · n 156 · Phase 4 · primary NCT02049814
  • -1.5% vs -0.7% wk 30 · n 138 · Phase 4 · primary NCT00993187
  • -0.9% vs -1.0% wk 24 · n 237 · Phase 4 · primary NCT01864174
  • -1.7% vs -1.1% wk 24 · n 224 · Phase 4 · primary NCT00751114
  • -0.7% vs -0.6% wk 24 · n 261 · Phase 4 · primary NCT01123980
  • 4.1% vs 3.4% wk 26 · n 46 · Phase 4 · primary NCT01966978
  • -0.5% vs -0.3% wk 4 · n 50 · Phase 4 · secondary NCT02429258
  • -0.8% vs -0.8% 5 mg once daily + metformin once daily · wk 8 · n 298 · Phase 4 · secondary NCT01438814
  • -0.3% vs -0.3% 5 mg once daily + metformin once daily · wk 2 · n 298 · Phase 4 · secondary NCT01438814
  • -0.5% vs -0.6% 0.2 mg · wk 6 · n 156 · Phase 4 · secondary NCT02049814
  • -1.9% vs -1.8% wk 24 · n 467 · Phase 4 · secondary NCT01117350
  • -1.3% vs -0.7% wk 4 · n 146 · Phase 4 · secondary NCT01917656
  • 1.9% vs 2.3% wk 12 · n 17 · Phase 4 · secondary NCT02007278
—Not reported
Body weight, change (kg)-0.4 vs -1.1vs Met5 mg once daily + metformin once daily · wk 14 · n 287NCT01438814
8 other results
  • 2.0 vs -3.0 wk 24 · n 474 · Phase 4 · secondary NCT01117350
  • -1.2 vs -1.4 0.2 mg · wk 12 · n 156 · Phase 4 · secondary NCT02049814
  • -0.6 vs -0.8 0.2 mg · wk 6 · n 156 · Phase 4 · secondary NCT02049814
  • -0.0 vs -0.2 0.2 mg · wk 2 · n 156 · Phase 4 · secondary NCT02049814
  • -0.8 vs 0.9 wk 30 · n 146 · Phase 4 · secondary NCT00993187
  • 0.4 vs -1.1 wk 24 · n 227 · Phase 4 · secondary NCT00751114
  • -5.4 vs -1.5 wk 4 · n 165 · Phase 4 · secondary NCT01917656
  • -0.6 vs 3.1 wk 26 · n 46 · Phase 4 · secondary NCT01966978
—Not reported
HbA1c below 7%48.4% vs 45.9%vs Liraglutidewk 24 · n 467NCT01117350
3 other results
  • 81.2% vs 40.1% wk 30 · n 138 · Phase 4 · secondary NCT00993187
  • 67.9% vs 41.9% wk 24 · n 224 · Phase 4 · secondary NCT00751114
  • 44% vs 20% wk 26 · n 46 · Phase 4 · secondary NCT01966978
—Not reported
Fasting plasma glucose, change0.3 vs 0.0+0.2 vs placebowk 12 · n 46NCT02099838
8 other results
  • -1.4 vs 0.2 wk 4 · n 50 · Phase 4 · secondary NCT02429258
  • -1.4 vs -1.5 5 mg once daily + metformin once daily · wk 14 · n 298 · Phase 4 · secondary NCT01438814
  • -2.6 vs -1.3 wk 30 · n 138 · Phase 4 · secondary NCT00993187
  • -1.2 vs -1.1 wk 24 · n 228 · Phase 4 · secondary NCT01864174
  • -3.6 vs -2.1 wk 24 · n 468 · Phase 4 · secondary NCT01117350
  • -3.4 vs -1.1 wk 24 · n 214 · Phase 4 · secondary NCT00751114
  • -0.1 vs 0.1 wk 4 · n 146 · Phase 4 · secondary NCT01917656
  • -1.8 vs -0.6 wk 4 · n 143 · Phase 4 · secondary NCT01917656
—Not reported
3-point MACE (% with event)—Not posted · NCT00004992—Not reported

HbA1c, change

metformin
0.2% vs 0.1%+0.1 vs placebowk 12 · n 46NCT02099838
14 other results
  • -1.0% vs -1.0% 5 mg once daily + metformin once daily · wk 14 · n 298 · Phase 4 · primary NCT01438814
  • -0.7% vs -0.9% 0.2 mg · wk 12 · n 156 · Phase 4 · primary NCT02049814
  • -1.5% vs -0.7% wk 30 · n 138 · Phase 4 · primary NCT00993187
  • -0.9% vs -1.0% wk 24 · n 237 · Phase 4 · primary NCT01864174
  • -1.7% vs -1.1% wk 24 · n 224 · Phase 4 · primary NCT00751114
  • -0.7% vs -0.6% wk 24 · n 261 · Phase 4 · primary NCT01123980
  • 4.1% vs 3.4% wk 26 · n 46 · Phase 4 · primary NCT01966978
  • -0.5% vs -0.3% wk 4 · n 50 · Phase 4 · secondary NCT02429258
  • -0.8% vs -0.8% 5 mg once daily + metformin once daily · wk 8 · n 298 · Phase 4 · secondary NCT01438814
  • -0.3% vs -0.3% 5 mg once daily + metformin once daily · wk 2 · n 298 · Phase 4 · secondary NCT01438814
  • -0.5% vs -0.6% 0.2 mg · wk 6 · n 156 · Phase 4 · secondary NCT02049814
  • -1.9% vs -1.8% wk 24 · n 467 · Phase 4 · secondary NCT01117350
  • -1.3% vs -0.7% wk 4 · n 146 · Phase 4 · secondary NCT01917656
  • 1.9% vs 2.3% wk 12 · n 17 · Phase 4 · secondary NCT02007278
Retagliptin/​metformin (Ruilintang)
—Not reported

Body weight, change (kg)

metformin
-0.4 vs -1.1vs Met5 mg once daily + metformin once daily · wk 14 · n 287NCT01438814
8 other results
  • 2.0 vs -3.0 wk 24 · n 474 · Phase 4 · secondary NCT01117350
  • -1.2 vs -1.4 0.2 mg · wk 12 · n 156 · Phase 4 · secondary NCT02049814
  • -0.6 vs -0.8 0.2 mg · wk 6 · n 156 · Phase 4 · secondary NCT02049814
  • -0.0 vs -0.2 0.2 mg · wk 2 · n 156 · Phase 4 · secondary NCT02049814
  • -0.8 vs 0.9 wk 30 · n 146 · Phase 4 · secondary NCT00993187
  • 0.4 vs -1.1 wk 24 · n 227 · Phase 4 · secondary NCT00751114
  • -5.4 vs -1.5 wk 4 · n 165 · Phase 4 · secondary NCT01917656
  • -0.6 vs 3.1 wk 26 · n 46 · Phase 4 · secondary NCT01966978
Retagliptin/​metformin (Ruilintang)
—Not reported

HbA1c below 7%

metformin
48.4% vs 45.9%vs Liraglutidewk 24 · n 467NCT01117350
3 other results
  • 81.2% vs 40.1% wk 30 · n 138 · Phase 4 · secondary NCT00993187
  • 67.9% vs 41.9% wk 24 · n 224 · Phase 4 · secondary NCT00751114
  • 44% vs 20% wk 26 · n 46 · Phase 4 · secondary NCT01966978
Retagliptin/​metformin (Ruilintang)
—Not reported

Fasting plasma glucose, change

metformin
0.3 vs 0.0+0.2 vs placebowk 12 · n 46NCT02099838
8 other results
  • -1.4 vs 0.2 wk 4 · n 50 · Phase 4 · secondary NCT02429258
  • -1.4 vs -1.5 5 mg once daily + metformin once daily · wk 14 · n 298 · Phase 4 · secondary NCT01438814
  • -2.6 vs -1.3 wk 30 · n 138 · Phase 4 · secondary NCT00993187
  • -1.2 vs -1.1 wk 24 · n 228 · Phase 4 · secondary NCT01864174
  • -3.6 vs -2.1 wk 24 · n 468 · Phase 4 · secondary NCT01117350
  • -3.4 vs -1.1 wk 24 · n 214 · Phase 4 · secondary NCT00751114
  • -0.1 vs 0.1 wk 4 · n 146 · Phase 4 · secondary NCT01917656
  • -1.8 vs -0.6 wk 4 · n 143 · Phase 4 · secondary NCT01917656
Retagliptin/​metformin (Ruilintang)
—Not reported

3-point MACE (% with event)

metformin
—Not posted · NCT00004992
Retagliptin/​metformin (Ruilintang)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Retagliptin/metformin (Ruilintang): no structured comparison results are available for Type 2 Diabetes.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. metformin: 4 of 4 rows · Retagliptin/metformin (Ruilintang): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricmetformin
Dropout rate
34.4%a
NCT01107717 · Phase 4 · registry result, not featured evidence · combination
show 39 more results
18.7%50mg Bid
NCT01528254 · Phase 4 · registry result, not featured evidence · combination
1.3%
NCT02561130 · Phase 4 · registry result, not featured evidence
—300 mg
NCT03267576 · Phase 4 · registry result, not featured evidence
45%
NCT01775813 · Phase 4 · registry result, not featured evidence
22%
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
0%
NCT01729156 · Phase 4 · registry result, not featured evidence
50%30 mg
NCT01972724 · Phase 4 · registry result, not featured evidence
—30 mg
NCT01972724 · Phase 4 · registry result, not featured evidence
47.4%15 mg
NCT01972724 · Phase 4 · registry result, not featured evidence
11.7%0.2 mg
NCT02049814 · Phase 4 · registry result, not featured evidence · combination
5.3%
NCT01864174 · Phase 4 · registry result, not featured evidence
—Metformin and Sitagliptin
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
0.7%Sitagliptin + Glargine (Hospital)
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
10%
NCT02007278 · Phase 4 · registry result, not featured evidence · combination
8.9%50mg once daily
NCT01766778 · Phase 4 · registry result, not featured evidence
6.6%50mg twice daily
NCT01766778 · Phase 4 · registry result, not featured evidence
4%
NCT02429258 · Phase 4 · registry result, not featured evidence
15.1%
NCT01917656 · Phase 4 · registry result, not featured evidence · combination
8.5%
NCT02099838 · Phase 4 · registry result, not featured evidence · combination
17.7%
NCT00993187 · Phase 4 · registry result, not featured evidence
10.8%BID + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
6.7%BID + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
6.2%OD + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
—1000 mg Once Daily
NCT01842620 · Phase 4 · registry result, not featured evidence
14%5 mg
NCT01512979 · Phase 4 · registry result, not featured evidence
11.9%5 mg + Metformin
NCT01512979 · Phase 4 · registry result, not featured evidence · combination
—Comparative Period: Insulin Glargi
NCT01117350 · Phase 4 · registry result, not featured evidence
—Extension Period: Insulin Glargine
NCT01117350 · Phase 4 · registry result, not featured evidence
8.6%Insulin Glargine
NCT01117350 · Phase 4 · registry result, not featured evidence
4.1%5 mg once daily + metformin once daily
NCT01438814 · Phase 4 · registry result, not featured evidence · combination
—Metformin
NCT00820573 · Phase 4 · registry result, not featured evidence
—Metformin Plus Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence · combination
15.2%
NCT00751114 · Phase 4 · registry result, not featured evidence
7.3%
NCT01123980 · Phase 4 · registry result, not featured evidence
12.8%Glucophage XR in Normal Weight Par
NCT00778622 · Phase 4 · registry result, not featured evidence
12.1%Glucophage XR in Obese Participant
NCT00778622 · Phase 4 · registry result, not featured evidence
12.3%Glucophage XR in Overweight Partic
NCT00778622 · Phase 4 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT01107717 · Phase 4 · registry result, not featured evidence · combination
show 39 more results
2.8%50mg Bid
NCT01528254 · Phase 4 · registry result, not featured evidence · combination
—
NCT02561130 · Phase 4 · registry result, not featured evidence
—300 mg
NCT03267576 · Phase 4 · registry result, not featured evidence
—
NCT01775813 · Phase 4 · registry result, not featured evidence
—
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
—
NCT01729156 · Phase 4 · registry result, not featured evidence
0%30 mg
NCT01972724 · Phase 4 · registry result, not featured evidence
—30 mg
NCT01972724 · Phase 4 · registry result, not featured evidence
5.3%15 mg
NCT01972724 · Phase 4 · registry result, not featured evidence
3.2%0.2 mg
NCT02049814 · Phase 4 · registry result, not featured evidence · combination
—
NCT01864174 · Phase 4 · registry result, not featured evidence
—Metformin and Sitagliptin
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Sitagliptin + Glargine (Hospital)
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—
NCT02007278 · Phase 4 · registry result, not featured evidence · combination
7.1%50mg once daily
NCT01766778 · Phase 4 · registry result, not featured evidence
6.6%50mg twice daily
NCT01766778 · Phase 4 · registry result, not featured evidence
—
NCT02429258 · Phase 4 · registry result, not featured evidence
6.4%
NCT01917656 · Phase 4 · registry result, not featured evidence · combination
—
NCT02099838 · Phase 4 · registry result, not featured evidence · combination
—
NCT00993187 · Phase 4 · registry result, not featured evidence
1.5%BID + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
1.5%BID + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
0%OD + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
—1000 mg Once Daily
NCT01842620 · Phase 4 · registry result, not featured evidence
1.3%5 mg
NCT01512979 · Phase 4 · registry result, not featured evidence
1.3%5 mg + Metformin
NCT01512979 · Phase 4 · registry result, not featured evidence · combination
—Comparative Period: Insulin Glargi
NCT01117350 · Phase 4 · registry result, not featured evidence
—Extension Period: Insulin Glargine
NCT01117350 · Phase 4 · registry result, not featured evidence
1.2%Insulin Glargine
NCT01117350 · Phase 4 · registry result, not featured evidence
0.9%5 mg once daily + metformin once daily
NCT01438814 · Phase 4 · registry result, not featured evidence · combination
—Metformin
NCT00820573 · Phase 4 · registry result, not featured evidence
—Metformin Plus Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence · combination
0.8%
NCT00751114 · Phase 4 · registry result, not featured evidence
0.4%
NCT01123980 · Phase 4 · registry result, not featured evidence
4%Glucophage XR in Normal Weight Par
NCT00778622 · Phase 4 · registry result, not featured evidence
5.6%Glucophage XR in Obese Participant
NCT00778622 · Phase 4 · registry result, not featured evidence
3.3%Glucophage XR in Overweight Partic
NCT00778622 · Phase 4 · registry result, not featured evidence
Serious AEs
0%a
NCT01107717 · Phase 4 · registry result, not featured evidence · combination
show 39 more results
16.6%50mg Bid
NCT01528254 · Phase 4 · registry result, not featured evidence · combination
3.9%
NCT02561130 · Phase 4 · registry result, not featured evidence
0%300 mg
NCT03267576 · Phase 4 · registry result, not featured evidence
0%
NCT01775813 · Phase 4 · registry result, not featured evidence
11.1%
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
0%
NCT01729156 · Phase 4 · registry result, not featured evidence
0%30 mg
NCT01972724 · Phase 4 · registry result, not featured evidence
3.9%30 mg
NCT01972724 · Phase 4 · registry result, not featured evidence
5.9%15 mg
NCT01972724 · Phase 4 · registry result, not featured evidence
1.2%0.2 mg
NCT02049814 · Phase 4 · registry result, not featured evidence · combination
2.8%
NCT01864174 · Phase 4 · registry result, not featured evidence
—Metformin and Sitagliptin
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
7.2%Sitagliptin + Glargine (Hospital)
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
0%
NCT02007278 · Phase 4 · registry result, not featured evidence · combination
3.6%50mg once daily
NCT01766778 · Phase 4 · registry result, not featured evidence
3.3%50mg twice daily
NCT01766778 · Phase 4 · registry result, not featured evidence
0%
NCT02429258 · Phase 4 · registry result, not featured evidence
1.3%
NCT01917656 · Phase 4 · registry result, not featured evidence · combination
2.1%
NCT02099838 · Phase 4 · registry result, not featured evidence · combination
5.5%
NCT00993187 · Phase 4 · registry result, not featured evidence
3.6%BID + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
2.6%BID + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
2.1%OD + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
0%1000 mg Once Daily
NCT01842620 · Phase 4 · registry result, not featured evidence
1.3%5 mg
NCT01512979 · Phase 4 · registry result, not featured evidence
1.9%5 mg + Metformin
NCT01512979 · Phase 4 · registry result, not featured evidence · combination
2.3%Comparative Period: Insulin Glargi
NCT01117350 · Phase 4 · registry result, not featured evidence
3.1%Extension Period: Insulin Glargine
NCT01117350 · Phase 4 · registry result, not featured evidence
—Insulin Glargine
NCT01117350 · Phase 4 · registry result, not featured evidence
0.6%5 mg once daily + metformin once daily
NCT01438814 · Phase 4 · registry result, not featured evidence · combination
0%Metformin
NCT00820573 · Phase 4 · registry result, not featured evidence
0%Metformin Plus Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence · combination
6.3%
NCT00751114 · Phase 4 · registry result, not featured evidence
0.8%
NCT01123980 · Phase 4 · registry result, not featured evidence
0.8%Glucophage XR in Normal Weight Par
NCT00778622 · Phase 4 · registry result, not featured evidence
0.8%Glucophage XR in Obese Participant
NCT00778622 · Phase 4 · registry result, not featured evidence
0%Glucophage XR in Overweight Partic
NCT00778622 · Phase 4 · registry result, not featured evidence
Most frequent reported AEs
a
nausea 25.2%
hypoglycemia 13.6%
peripheral edema 4.9%
NCT01107717 · Phase 4 · registry result, not featured evidence · combination
show 33 more results
50mg Bid
back pain 10.5% (placebo 8.6%)
diarrhoea 10.4% (placebo 10.4%)
nasopharyngitis 10.4% (placebo 10.8%)
NCT01528254 · Phase 4 · registry result, not featured evidence · combination
genitourinary infection 5.2%
abdominal pain 3.9%
injury 3.9%
NCT02561130 · Phase 4 · registry result, not featured evidence
300 mg
fatigue 3.2%
diarrhoea 1.6%
discomfort 1.6%
NCT03267576 · Phase 4 · registry result, not featured evidence
bloating 35% (placebo 29.2%)
nausea 35% (placebo 45.8%)
diarrhea 30% (placebo 41.7%)
NCT01775813 · Phase 4 · registry result, not featured evidence
gi 77.8%
headache 25.9%
other ae 7.4%
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
fractured vertebral column 0% (placebo 8.3%)
gastrointestinal uncomfort 0% (placebo 0%)
NCT01729156 · Phase 4 · registry result, not featured evidence
30 mg
oedema 11.8%
eyelid oedema 5.9%
folliculitis 5.9%
NCT01972724 · Phase 4 · registry result, not featured evidence
30 mg
conjunctival haemorrhage 0%
eyelid oedema 0%
folliculitis 0%
NCT01972724 · Phase 4 · registry result, not featured evidence
15 mg
conjunctival haemorrhage 5.9%
ligament injury 5.9%
nasopharyngitis 5.9%
NCT01972724 · Phase 4 · registry result, not featured evidence
0.2 mg
flatulence 9.3%
urinary tract infection 6%
NCT02049814 · Phase 4 · registry result, not featured evidence · combination
diarrhoea 8.8%
NCT01864174 · Phase 4 · registry result, not featured evidence
urinary tract infection 1.4%
wound infection 0%
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
influenza like illness 15%
headache 10%
arthralgia 5%
NCT02007278 · Phase 4 · registry result, not featured evidence · combination
50mg once daily
upper respiratory tract infection 14.3%
cough 3.6%
dizziness 3.6%
NCT01766778 · Phase 4 · registry result, not featured evidence
50mg twice daily
cough 3.3%
elevated liver function test 3.3%
hyperkalemia 3.3%
NCT01766778 · Phase 4 · registry result, not featured evidence
urinary tract infection 6% (placebo 6%)
NCT02429258 · Phase 4 · registry result, not featured evidence
vomiting 5.3%
NCT01917656 · Phase 4 · registry result, not featured evidence · combination
abnormal liver function 13% (placebo 5.9%)
hypoglycemia 2.2% (placebo 3.9%)
NCT02099838 · Phase 4 · registry result, not featured evidence · combination
dyspepsia 13%
diarrhoea 10.3%
nasopharyngitis 8.9%
NCT00993187 · Phase 4 · registry result, not featured evidence
influenza 5.7%
nasopharyngitis 4.7%
diarrhoea 4.2%
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
headache 5.7%
nasopharyngitis 5.7%
influenza 2.6%
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
diarrhoea 5.3%
influenza 5.3%
headache 4.2%
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
1000 mg Once Daily
transient headache 4%
NCT01842620 · Phase 4 · registry result, not featured evidence
5 mg
dyslipidaemia 14%
hyperglycaemia 12.7%
urinary tract infection 8.9%
NCT01512979 · Phase 4 · registry result, not featured evidence
5 mg + Metformin
dyslipidaemia 8.8%
headache 6.3%
urinary tract infection 6.3%
NCT01512979 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 7.9%
headache 5%
diarrhoea 3.7%
NCT01117350 · Phase 4 · registry result, not featured evidence
nasopharyngitis 7.5%
diarrhoea 3.1%
headache 1.3%
NCT01117350 · Phase 4 · registry result, not featured evidence
5 mg once daily + metformin once daily
diarrhoea 18%
abdominal pain 6.7%
nausea 6.7%
NCT01438814 · Phase 4 · registry result, not featured evidence · combination
headache 6.3%
influenza 3.4%
nasopharyngitis 3.4%
NCT00751114 · Phase 4 · registry result, not featured evidence
nasopharyngitis 10%
NCT01123980 · Phase 4 · registry result, not featured evidence
diarrhea 14.4%
abdominal distension 4.8%
dizziness 4.8%
NCT00778622 · Phase 4 · registry result, not featured evidence
hyperuricemia 4.8%
diarrhea 3.2%
dizziness 3.2%
NCT00778622 · Phase 4 · registry result, not featured evidence
abdominal discomfort 10.7%
diarrhea 9.8%
abdominal distension 7.4%
NCT00778622 · Phase 4 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

metformin

HbA1c 6.9% (n=103) vs 6.4% (n=114) Conventional Therapy @ 156wk
absolute value · percentage points
NCT01107717 · Phase 4 · registry result, not featured evidence · combination
Treatment Failure 32% (n=103) vs 51.8% (n=114) Conventional Therapy @ 156wk
event count · % of participants
NCT01107717 · Phase 4 · registry result, not featured evidence · combination · converted to % from 33 number of participants as posted
Time to Treatment Failure 7.81% (n=983) vs 19.97% (n=989) placebo @ 52wk50mg Bid
absolute value · percentage points
NCT01528254 · Phase 4 · registry result, not featured evidence · combination
Time to Treatment Failure 17.79% (n=983) vs 34.67% (n=989) placebo @ 104wk50mg Bid
absolute value · percentage points
Year 2
NCT01528254 · Phase 4 · registry result, not featured evidence · combination
Time to Treatment Failure 31.24% (n=983) vs 48.31% (n=989) placebo @ 156wk50mg Bid
absolute value · percentage points
Year 3
NCT01528254 · Phase 4 · registry result, not featured evidence · combination
Time to Treatment Failure 39.84% (n=983) vs 59.29% (n=989) placebo @ 208wk50mg Bid
absolute value · percentage points
Year 4
NCT01528254 · Phase 4 · registry result, not featured evidence · combination
Time to Treatment Failure 46.41% (n=983) vs 66.57% (n=989) placebo @ 260wk50mg Bid
absolute value · percentage points
Year 5
NCT01528254 · Phase 4 · registry result, not featured evidence · combination
Glycemic Control Failure 0.24% (n=983) vs 0.27% (n=989) placebo50mg Bid
absolute value · percentage points
NCT01528254 · Phase 4 · registry result, not featured evidence · combination
show 3 more results
1.11% (n=410) vs 1.02% (n=588) placebo50mg Bid
NCT01528254 · Phase 4 · registry result, not featured evidence · combination
0.25% (n=983) vs 0.26% (n=989) placebo50mg Bid
NCT01528254 · Phase 4 · registry result, not featured evidence · combination
1.27% (n=410) vs 0.99% (n=588) placebo50mg Bid
NCT01528254 · Phase 4 · registry result, not featured evidence · combination
HOMA-B -1.04% (n=228) vs -0.46% (n=227) placebo50mg Bid
absolute change · percentage points
From Week 13 to end of study
NCT01528254 · Phase 4 · registry result, not featured evidence · combination
Insulin Sensitivity -6.39% (n=228) vs -1.01% (n=227) placebo50mg Bid
percent change · % of baseline
From Week 13 to end of study
NCT01528254 · Phase 4 · registry result, not featured evidence · combination
Drug-free Diabetes Remission 24.7% (n=77) @ 24wk
responder rate · % of participants
No placebo or comparator arm
NCT02561130 · Phase 4 · registry result, not featured evidence · converted to % from 19 Participants as posted
show 1 more result
14.3% (n=77) @ 64wk*
NCT02561130 · Phase 4 · registry result, not featured evidence · converted to % from 11 Participants as posted
HbA1c Less Than 6 7.8% (n=77) @ 24wk
event count · % of participants
No placebo or comparator arm
NCT02561130 · Phase 4 · registry result, not featured evidence · converted to % from 6 Participants as posted

+ 72 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: metformin's landscape · Retagliptin/metformin (Ruilintang)'s landscape